Delavirdine: profile and news

Multi-component drug delivery system: An emerging trend Feb 8, 2006
Non-nucleoside Reverse Transcriptase Inhibitors (NnRTIs), which include delavirdine (Rescriptor), efavirenz (Sustiva), and nevirapine (Viramune). ... - Express Pharma Pulse,

T-20 helps to prevent mother-to-child transmission of HIV in women ... Jan 19, 2006
...major resistance mutations and the woman was provided with an anti-HIV treatment regimen consisting of abacavir (Ziagen), delavirdine, fosamprenavir (Telzir ... - Aidsmap,

Lexiva for the treatment of HIV infection in adults in combination ... Jan 19, 2006
Lexiva. Lexiva should not be coadministered with Rifampin, St. John'swort, Lovastatin, Simvastatin or Delavirdine. Particular caution ... - Xagena.it,

Psychiatric Manifestations of HIV Infection and AIDS Dec 5, 2005
The other members of the NNRTI medication class, delavirdine (Rescriptor) and nevirapine (Viramune), have not been associated with significant CNS adverse ... - Psychiatric Times,

FDA Approves Updated Labeling for LEXIVA Nov 18, 2005
LEXIVA. LEXIVA should not be coadministered with rifampin, St. John's wort, lovastatin, simvastatin or delavirdine. Particular caution ... - Finanzen.net,

Anti-HIV drug from rainforest almost lost before its discovery Sep 13, 2005
NNRTIs include Viramune® (nevirapine) from Boehringer Ingelheim, Sustiva® (efavirenz) from Bristol-Myers Squibb, and Rescriptor® (delavirdine) from Pfizer. ... - Mongabay.com

IAS: The New York Patient - source found but mysteries remain Jul 26, 2005
Like the Index Patient (and contrary to the initial press reports), he remained sensitive to the NNRTI drugs efavirenz and delavirdine. ... - Aidsmap

Study Results Presented on Pharmacokinetics of Once-Daily HIV ... Jul 26, 2005
LEXIVA. LEXIVA should not be coadministered with rifampin, St. John's wort, lovastatin, simvastatin, or delavirdine. Particular ... - Yahoo News (press release)

HAART & the Molecular Biology of AIDS Dementia Complex May 20, 2005
...their effectiveness71. Approved and commonly used drugs in this class include nevirapine, delavirdine and efavirenz. Nevirapine ... - RedNova.com,

Other information

Indication
For the treatment of HIV-1 infection in combination with appropriate antiretroviral agents when therapy is warranted

Pharmacology
Delavirdine is a non-nucleoside reverse transcriptase inhibitor (nNRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Delavirdine binds directly to reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by causing a disruption of the enzyme's catalytic site. The activity of Delavirdine does not compete with template or nucleoside triphosphates. HIV-2 RT and eukaryotic DNA polymerases (such as human DNA polymerases alpha, beta, or sigma) are not inhibited by Delavirdine.

Mechanism Of Action
Delavirdine binds directly to viral reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by disrupting the enzyme's catalytic site.

Drug Category
Anti-HIV Agents; Nonnucleoside Reverse Transcriptase Inhibitors; ATC:J05AG02

Brand Names/Synonyms
BHAP-U 90152; Bhap Der; DLV; Delavirdine; Rescriptor; SPP

Dosage Forms
caplets

Absorption
rapidly absorbed

Interactions
Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.

Chemical IUPAC Name
N-[2-[4-[3-(1-methylethylamino)pyridin-2-yl]piperazin-1-yl]carbonyl-1H-indol-5-yl]methanesulfonamide

Chemical Formula
C22H28N6O3S

Half Life
5.8 hours

Drug Type
Approved Drug

# Accession No
APRD00149

CAS Registry Number
136817-59-9